Cost-effectiveness Analysis of Levofloxacin and Gatifoxacin in the Treatment of Lower Respiratory Tract Infections / 药物流行病学杂志

ABSTRACT

Objective:To evaluate the cost-effectiveness of levofloxacin and gatifoxacin in the treatment of lower respiratory tract infections.Method:The clinical data of levofloxacin and gatifoxacin in the treatment of lower respiratory tract infections were collected with the evidence-based medicine method and were evaluated with pharmacoeconomic cost-effectiveness analysis.Result:The cure rates of two drugs were 64.29%(57.70%,70.88%),and 81.43%(70.05%, 92.81%)and the cost-effectiveness ratios were 1.90 and 5.79 respectively.The?C/?E was 20.37.Conclusion:The cost-effectiveness analysis indicated that the cost-effectivenss ratio of levofloxacin is superior to that of gatifoxacin though the cure efficacy of gatifoxacin for lower respiratory tract infections is better.